Participant Age Range
50 years and older
“The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population”
The purpose and rationale is to evaluate the safety and performance of the GRAIL Multi-Cancer Early Detection (MCED) Test in an eligible screening population. All participants will be actively followed by the enrolling institution for 3 years to assess for cancer status, uptake of routine cancer screening and other data collection with analyses performed at interim time points. In addition to a baseline questionnaire, additional participant-reported outcomes will be collected at multiple time points before and after test results are returned.